MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$2,532,518
Free Cash flow
-$2,532,195
Unit: Dollar
Positive Cash Flow Breakdown
Accounts payable
Interest income
Negative Cash Flow Breakdown
Prepaid expenses and other curre...
Purchases of property and equipm...
Inventories
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Total research and development
212,563
383,724
526,620
504,387
Total selling, general and administrative
2,801,004
1,542,658
1,373,773
3,469,842
Interest income
46,504
78,676
38,505
176,536
Net loss
-2,967,063
-1,847,706
-1,861,888
-1,691,989
Stock-based compensation
41,780
43,278
29,469
37,841
Prepaid expenses and other current assets
166,325
85,431
-65,435
247,697
Inventories
56,643
93,091
-
-
Other assets
35,330
-
-
-
Accounts payable
782,687
-51,128
-83,967
52,727
Accrued and other current liabilities
-20,634
-445,640
521,754
45,303
Total adjustments to reconcile net loss to net cash used in operations
-
-
-
-111,826
Net cash used in operating activities
-2,421,528
-2,479,718
-1,329,197
-1,803,815
Purchases of property and equipment
110,667
-
-
-
Net cash used in investing activities
-110,667
-
-
-
Proceeds from issuance of common stock, pre-funded warrants, and warrants, net of issuance costs
-
-
4,187,048
-12,621
Proceeds from issuance of common stock from atm sales, net of issuance costs
-323
1,994,374
-
-
Payment of issuance costs
0
91,352
0
0
Proceeds from exercise of pre-funded warrants
-
-
0
0
Payment for fractional shares in reverse stock split
-
-
0
-367
Net cash provided by financing activities
-323
1,903,022
4,187,048
-12,988
Net increase (decrease) in cash and cash equivalents
-2,532,518
-576,696
2,857,851
-1,816,803
Cash and cash equivalents at beginning of period
6,945,282
7,521,978
4,664,127
3,161,570
Cash and cash equivalents at end of period
4,412,764
6,945,282
7,521,978
4,664,127
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash and cash...
-$2,532,518
(-176.30%↓ Y/Y)
Accounts payable
$782,687
(319.35%↑ Y/Y)
Stock-based compensation
$41,780
(-45.33%↓ Y/Y)
Net cash used in
operating activities
-$2,421,528
(47.64%↑ Y/Y)
Net cash used in
investing activities
-$110,667
Net cash provided by
financing activities
-$323
(-100.00%↓ Y/Y)
Canceled cashflow
$824,467
Interest income
$46,504
(-56.88%↓ Y/Y)
Net loss
-$2,967,063
(25.91%↑ Y/Y)
Purchases of property and
equipment
$110,667
Proceeds from issuance of
common stock from atm...
-$323
Canceled cashflow
$46,504
Prepaid expenses and
other current assets
$166,325
(178.19%↑ Y/Y)
Inventories
$56,643
Other assets
$35,330
Accrued and other
current liabilities
-$20,634
(96.26%↑ Y/Y)
Total selling,
general and...
$2,801,004
Total research and
development
$212,563
(-88.81%↓ Y/Y)
Buy us a coffee
Dermata Therapeutics, Inc. (DRMA)
Dermata Therapeutics, Inc. (DRMA)